What Are Peptides Good For? Goal by Goal, Graded (2026)

Most people arriving at this question do not want a definition. They have a goal — lose fat, fix a tendon, add muscle, sleep better, age slower — and they want to know whether a peptide is a real option for it or a marketing story with a needle attached.

So this page is organised by goal rather than by molecule, and each one is graded on the same standard: is there controlled human evidence that a peptide improves this outcome in people like you? Not a mechanism. Not a rodent. Not a testimonial. That standard sorts the category quickly, and the result is uncomfortable for the market: one goal comes back strong, one comes back genuinely narrow, and the rest come back empty despite being where almost all the money is spent.

Weight loss — strong evidence, with a caveat about what you lose

This is the one unambiguous win, and it is not close.

The incretin drugs — semaglutide, tirzepatide and the investigational agents behind them — are peptides, and they produce weight loss at a scale nothing else in this category approaches. In STEP 1, mean body-weight change over 68 weeks was −14.9% with once-weekly semaglutide versus −2.4% on placebo across 1,961 adults¹. In SURMOUNT-1, tirzepatide reached −20.9% at its highest dose over 72 weeks against −3.1% for placebo across 2,539 adults².

The caveat is about composition rather than quantity. A 2026 systematic review of 35 randomised trials found the median proportion of total weight loss attributable to muscle-based indices was 28.3% in the incretin arms, with about two thirds exceeding the review's benchmark — though notably 38% of the lifestyle and placebo comparator groups exceeded their benchmark too, and no included study measured objective physical function³. So: real, large, and not free. We work through what that means for anyone who lifts in peptides for weight loss and muscle gain, and the practical question of which vial you are actually buying in peptide injections for weight loss.

Grade: strong — for weight loss, in people with obesity, using approved medicines under prescription.

Muscle growth — no

Here the evidence runs the opposite way, and it does so despite an enormous amount of confident marketing.

The GH-axis peptides raise growth hormone and IGF-1. That much is genuine and measurable on a lab panel. What has repeatedly failed to follow is added muscle or strength in healthy, training adults. We lay out that surrogate-marker collapse in which muscle-growth peptides survive contact with the human trials and sermorelin for muscle growth and bodybuilding.

The deeper problem is that nobody has run the study that would settle it. There is no controlled trial in healthy, training adults showing a peptide adding muscle mass. What exists is a mechanism that behaves exactly as advertised and an outcome that does not arrive.

Grade: none — mechanism confirmed, outcome absent.

Injury and tendon repair — the biggest gap between belief and data

This is where the athletic peptide market lives, and where the disparity between confidence and evidence is widest.

The preclinical work is genuinely substantial. A 2025 narrative review of BPC-157 for musculoskeletal healing describes regenerative properties across numerous animal models, working through VEGFR2 and nitric oxide signalling to promote angiogenesis and fibroblast activity, particularly in poorly vascularised tissue like tendon. And then the same review states the position plainly: human data are extremely limited, with only three pilot studies examining BPC-157 in humans⁴.

That is the entire human basis for the most popular recovery peptide in the world. The full picture is in BPC-157 for healing and recovery: what the evidence shows, and the same shape repeats for TB-500 and across the injury-specific pages we maintain, from rotator cuff to Achilles and knee.

Grade: weak — compelling animal data, three human pilot studies, no controlled outcome trial.

Longevity and NAD+ — biological activity, absent outcomes

The anti-aging tier deserves its own grade because it fails in an unusually specific way: the compounds demonstrably do the biochemical thing they claim, and it demonstrably does not translate.

A systematic review of NAD+ supplementation covering 113 studies found that oral nicotinamide riboside and nicotinamide mononucleotide consistently demonstrated biochemical target engagement and were generally well tolerated — while effects on functional, metabolic, vascular and other healthspan-relevant outcomes were heterogeneous and often null⁵. A separate meta-analysis in older adults concluded that current evidence does not support NMN or NR supplementation for preserving muscle mass and function⁶.

That is the textbook definition of a surrogate marker moving without an outcome following. We go through the injectable end of this specifically in NAD+ injections: what the evidence shows.

Grade: weak — target engagement demonstrated, healthspan outcomes not.

Sleep, cognition, immunity — mechanism stories with thin human data

The peptides marketed for sleep, focus and immune support are individually varied but share a pattern: a plausible mechanism, limited or foreign-standard clinical literature, and no controlled trial supporting the use being sold. Our reviews of DSIP for sleep, Semax vs Selank and thymosin alpha-1 in athletes go through each honestly, including the cases where a legitimate clinical drug is being repurposed into a claim it was never tested for.

Grade: weak to none, depending on compound.

What peptides are unambiguously good for

Zoom out from the athletic market and the honest answer changes character entirely.

Peptides are good for treating disease, and they have been for a century. Insulin therapy began in the 1920s; today over 60 peptide drugs are approved in the United States and other major markets and more than 150 are in active clinical development⁷. Diabetes, obesity, osteoporosis, several cancers, HIV-associated conditions — these are real, approved, evidence-backed peptide medicines.

What peptides are not established as good for is optimising a healthy body. Almost every approved peptide drug treats a defined pathology in a diagnosed patient. The moment the target becomes a healthy person seeking improvement rather than treatment, the evidence base thins out dramatically — and that transition, not the molecules, is what separates the two halves of this subject.

The two constraints that apply to all of it

Not FDA-approved is the default here. Outside the approved drugs, the compounds discussed above are either compounded preparations — which are not FDA-approved products even when a licensed pharmacy makes them against a prescription — or unapproved research chemicals. The distinction matters and we cover it in are peptides legal?.

Tested athletes should stop earlier than everyone else. The GH-axis peptides, tissue-repair peptides and research-tier metabolic compounds are banned in tested sport, year-round, and a prescription does not change that. Check specific compounds with our prohibited-substance checker.

The honest summary

One goal has strong evidence: weight loss, with approved incretin medicines, in people with obesity, and with a real lean-mass cost. One category — approved peptide medicines for diagnosed disease — has a century of evidence and is not what anyone means by this question. Everything else that this market sells to healthy people for muscle, repair, sleep and longevity sits somewhere between "mechanism confirmed, outcome absent" and "nobody has looked."

That is not a claim these compounds do nothing. It is the observation that after decades of interest and a great deal of money, the studies that would show they do something have mostly not been run — and a market this large having produced this little human data is itself a finding worth sitting with.